Skip to main content

Table 1 Patient demographic and tumour characteristics

From: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

   n = 32(%)
Age, mean ± SD   53.6 ± 12.2
Hormone receptor positive 14 (43.8)
negative 18 (56.2)
TNBC   16 (50)
PS 0 19 (59.4)
1 13 (40.6)
Prior treatment Anthracycline 23 (71.9)
Taxane 29 (90.6)
Prior regimen number 0 11 (34.4)
1 14 (43.8)
2 7 (21.9)
Visceral metastasis present 22 (68.8)
Number of metastases 1 28 (87.5)
2 2 (6.3)
3 1 (3.1)
4 1 (3.1)
Metastatic sites Liver 14
Lymph node 10
Lung 8
Skin 3
Pleural 1
Breast 1
Thyroid 1
Spleen 1
  1. Abbreviations: OR Oestrogen receptor, PgR Progesterone receptor, HER-2 Human epidermal growth factor receptor 2, PS Performance status
\